Who
Jonathan S. Wolin
Officer
Company insider
Files Form 4 as: Chief of Staff, CCO & GC, Jaguar Health.
In numbers
- Trades disclosed
- 28
- Buys
- 1
- Sells
- 0
- Bought
- $10
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 20 Mar 2020
- Last trade
- 11 Dec 2025
- Last filed
- 21 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Dec 2025filed 21 Jan 2026 | JAGX Jaguar HealthBiotechnology | SEC FORM 4 Code A | —11,740 at $0.00 | filing |
| 11 Dec 2025filed 21 Jan 2026 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,740 at $0.00 | filing |
| 11 Dec 2025filed 21 Jan 2026 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,740 at $0.00 | filing |
| 11 Dec 2025filed 21 Jan 2026 | JAGX Jaguar HealthBiotechnology | SEC FORM 4 Code A | —11,740 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code D | $450.0M9,000 at $50,000.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code A | $473.1M9,462 at $50,000.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,262 | filing |
| 31 Mar 2025filed 2 Apr 2025 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code P | $450.0M9,000 at $50,000.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code P | —9,000 | filing |
| 8 Oct 2024filed 10 Oct 2024 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,376 at $0.00 | filing |
| 8 Oct 2024filed 10 Oct 2024 | JAGX Jaguar HealthBiotechnology | SEC FORM 4 Code A | —4,922 at $0.00 | filing |
| 17 May 2024filed 21 May 2024 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code M | —871 at $0.00 | filing |
| 17 May 2024filed 21 May 2024 | JAGX Jaguar HealthBiotechnology | SEC FORM 4 Code M | —871 | filing |
| 5 Apr 2024filed 17 Apr 2024 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code A | —89 at $0.00 | filing |
| 5 Apr 2024filed 17 Apr 2024 | JAGX Jaguar HealthBiotechnology | SEC FORM 4 Code M | —89 | filing |
| 14 Aug 2023filed 14 Aug 2023 | JAGX Jaguar HealthBiotechnology | SEC FORM 4 Code A | —196,628 at $0.00 | filing |
| 17 May 2023filed 19 May 2023 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code M | —871 at $0.00 | filing |
| 17 May 2023filed 19 May 2023 | JAGX Jaguar HealthBiotechnology | SEC FORM 4 Code M | —871 | filing |
| 5 Apr 2023filed 20 Apr 2023 | JAGX Jaguar Healthoption or derivative · Biotechnology | SEC FORM 4 Code A | —88 at $0.00 | filing |
| 5 Apr 2023filed 20 Apr 2023 | JAGX Jaguar HealthBiotechnology | SEC FORM 4 Code M | —88 | filing |
News
Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) ...JAGX · pr-inside.com · 21 Oct 2026Jaguar Health, Inc.: Jaguar Health Provides Update Regarding Special Stock DividendJAGX · finanznachrichten.de · 14 Oct 2026Reminder: Today, October 13, 2026, is the Record Date for Jaguar Health's Special Stock DividendJAGX · tennesseedaily.com · 13 Oct 2026
0 headlines in the last 90 days name Jonathan S. Wolin; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.